March 2025 - BioMedWire (BMW)

FridayMar 28, 2025 1:00 pm

Adageis Simplifies Value-Based Care for Healthcare Providers

Adageis makes it easier for providers to identify and obtain the most profitable reimbursements while maintaining high-quality value-based care. The company’s platform enables providers to receive the full payments they deserve by advocating on their behalf with insurers. Adageis offers seamless integration – the platform works with over 90 electronic health record (“EHR”) systems, eliminating the need for disruptive system changes. The company is working with investors to develop new solutions to support small and independent healthcare practices. Healthcare providers often struggle with complex reimbursement structures, making it difficult to optimize cash flow while ensuring high-quality value-based patient care. Adageis…

FridayMar 28, 2025 10:00 am

Report Shows the Growth of Medicare Advantage Plans is Decelerating

A recently published report indicates that the rate at which Medicare Advantage plans are growing is slowing down. The report was authored by HealthScape Advisors, a consulting company, together with Chartis, a healthcare advisory company. The report says the Medicare Advantage (MA) market is experiencing a correction following the explosive growth the segment experienced over the past four years. Data shows that people enrolled in MA plans increased by 3.9% (1.3 million enrollees) last year. This is in contrast to the 7% rate of growth registered in 2023, which was also a reduction from the growth rate of 9.4% recorded…

ThursdayMar 27, 2025 10:00 am

Firefighters Have an Increased Chance of Having Gene Mutations Associated with Brain Cancer, Study Says

New research shows that firefighters diagnosed with gliomas tend to have a particular set of genetic mutations that aren’t so common in individuals engaged in other occupations. In the past, those specific gene mutations had been linked to haloalkane exposure. Haloalkanes are chemicals often used in fire extinguishers and fire retardants. This study is the first one ever to confirm that haloalkane exposure is a possible risk factor heralding the development of gliomas. Gliomas have proven to be difficult to treat. The study lead, Prof. Elizabeth Claus, based at Yale School of Public Health, explains that their study is the…

ThursdayMar 27, 2025 9:45 am

Clene Inc.’s (NASDAQ: CLNN) Q1 Virtual Investor Summit Presentation Available for On-Demand Viewing

Clene’s presentation by CEO Rob Etherington and CFO Morgan Brown is now available on demand on the event’s website, covering the company’s recent achievements and immediate plans for lead drug candidate CNM-Au8®. Clene is planning to submit a New Drug Application (“NDA”) to the FDA for potential accelerated approval for CNM-Au8 for ALS in the second half of 2025. The company recently released the latest data from a cross-regimen analysis of HEALEY ALS Platform Trial, showing that CNM-Au8 significantly extends survival in patients with ALS. Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical…

WednesdayMar 26, 2025 2:20 pm

Meeting the Healthcare Demands of America’s Growing AAPI Elderly Population

A Strategic Approach to Addressing a Critical Demographic Shift Mrs. Lin, a 72-year-old Korean-American retiree, has lived in the same neighborhood for decades. She visits her longtime physician, a trusted figure in the community, for regular checkups. However, with many private-practice doctors retiring and younger physicians moving into large corporate healthcare settings, she now struggles to navigate an unfamiliar system that doesn’t always cater to her cultural and linguistic needs. Her story reflects a growing challenge for AAPI seniors across the country as the healthcare system struggles to keep pace with their specific needs. By 2060, the number of Asian…

TuesdayMar 25, 2025 10:00 am

New Study Finds Possible Explanation for Higher Parkinson’s Prevalence in Men

Scientists have for long been baffled as to why men have a higher likelihood of developing Parkinson’s disease when compared to women. A new study suggests a possible reason why this higher risk exists, and the culprit is a usually harmless protein within the brain. PINK1, or PTEN-induced kinase 1, is a protein that is involved in regulating the energy use of brain cells. Under normal circumstances, this protein isn’t a threat. However, as this new study found, the immune system in some people with Parkinson’s disease mistakes these proteins to be threats and attacks brain cells found to be…

FridayMar 21, 2025 10:00 am

New Study Shows ‘Viral Mimicry’ Could Transform Glioblastoma Treatment

Glioblastoma continues to be one of the most challenging cancers to treat as it resists even the latest innovations in immunotherapy. Now, a new study conducted by a team at the Sylvester Comprehensive Cancer Center at the University of Miami suggests that, when a specific protein is suppressed, an antiviral immune response increases the effectiveness of immune checkpoint inhibitors. This discovery not only opens the door to a novel way to treat glioblastoma but also suggests that the protein in question, ZNF638, could be a valuable biomarker as treatment teams customize immunotherapy for specific patients. The research findings appeared in…

ThursdayMar 20, 2025 10:00 am

Study Shows Bioengineered Materials Can Treat Oral Mucositis

New research that appeared in the journal Oncotarget has opened the door to a new way to approach the treatment of oral ulcers induced by chemotherapy. This debilitating and painful side effect of cancer treatment lowers the quality of life of patients undergoing chemotherapy, but oral mucositis remains an unmet medical need. The study was conducted by a joint team from the Center for Research in Physics in Brazil and others from Rio de Janeiro Federal University. The lead author was Ana Chor. They sought to examine how effective an electrospun poly membrane (PLGA) was in accelerating tissue regeneration in…

ThursdayMar 20, 2025 9:00 am

Adageis on Track to Exceed Q1 Growth Target, Expanding Healthcare AI Platform

Adageis is surpassing its Q1 2025 growth targets, reflecting expanding market demand, with investment focused on team expansion, financial infrastructure, and AI development. Adageis’ patented AI-driven platform, already covering over 250,000 patient lives, optimizes quality healthcare for patients and revenue for healthcare providers. The company projects 580,000 patient lives covered by the end of Q2 2025. Adageis, a healthcare technology company reshaping patient care through flexible AI-centric software solutions for healthcare organizations, is set to exceed its Q1 2025 growth expectations as its AI-powered platform continues to gain traction in the healthcare sector. The company now covers more than 250,000…

WednesdayMar 19, 2025 9:00 am

Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Delivers Significant Survival Benefits in New Analyses of Healey ALS Platform Trial Data

Clene's CNM-Au8® treatment was demonstrated to improve survival in ALS patients by up to 14.8 months. The findings come from a post hoc analysis of the HEALEY ALS Platform Trial, comparing CNM-Au8 to a concurrently enrolled control. Strong survival benefit was observed in patients meeting the planned criteria for Clene’s upcoming Phase 3 RESTORE-ALS trial. The company is preparing to submit a New Drug Application (“NDA”) to the FDA later this year for potential accelerated approval, and further regulatory discussions and a confirmatory Phase 3 trial are planned for mid-2025. Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine…